PortfoliosLab logoPortfoliosLab logo
ACAD vs. TPR
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ACAD vs. TPR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ACADIA Pharmaceuticals Inc. (ACAD) and Tapestry, Inc. (TPR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ACAD achieves a -21.79% return, which is significantly lower than TPR's 8.81% return. Over the past 10 years, ACAD has underperformed TPR with an annualized return of -5.32%, while TPR has yielded a comparatively higher 16.60% annualized return.


ACAD

1D
-2.93%
1M
-4.83%
YTD
-21.79%
6M
-17.85%
1Y
-2.68%
3Y*
-5.32%
5Y*
-2.17%
10Y*
-5.32%

TPR

1D
-0.12%
1M
-2.87%
YTD
8.81%
6M
27.68%
1Y
79.04%
3Y*
52.28%
5Y*
29.92%
10Y*
16.60%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ACAD vs. TPR - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ACAD
ACADIA Pharmaceuticals Inc.
-21.79%45.56%-41.39%96.67%-31.79%-56.34%24.96%164.56%-46.30%4.40%
TPR
Tapestry, Inc.
8.81%98.73%82.80%0.16%-3.32%32.29%16.86%-15.97%-22.09%30.48%

Correlation

The correlation between ACAD and TPR is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.26

Correlation (3Y)
Calculated over the trailing 3-year period

0.23

Correlation (5Y)
Calculated over the trailing 5-year period

0.27

Correlation (10Y)
Calculated over the trailing 10-year period

0.22

Correlation (All Time)
Calculated using the full available price history since May 28, 2004

0.23

Fundamentals

Market Cap

ACAD:

$3.61B

TPR:

$28.88B

EPS

ACAD:

$2.20

TPR:

$3.15

PE Ratio

ACAD:

9.50

TPR:

44.00

PS Ratio

ACAD:

3.26

TPR:

3.71

PB Ratio

ACAD:

2.89

TPR:

42.32

Total Revenue (TTM)

ACAD:

$1.10B

TPR:

$7.85B

Gross Profit (TTM)

ACAD:

$758.58M

TPR:

$5.98B

EBITDA (TTM)

ACAD:

$104.56M

TPR:

$1.06B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ACAD vs. TPR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACAD
ACAD Risk / Return Rank: 3535
Overall Rank
ACAD Sharpe Ratio Rank: 3737
Sharpe Ratio Rank
ACAD Sortino Ratio Rank: 3333
Sortino Ratio Rank
ACAD Omega Ratio Rank: 3232
Omega Ratio Rank
ACAD Calmar Ratio Rank: 3737
Calmar Ratio Rank
ACAD Martin Ratio Rank: 3737
Martin Ratio Rank

TPR
TPR Risk / Return Rank: 8585
Overall Rank
TPR Sharpe Ratio Rank: 8787
Sharpe Ratio Rank
TPR Sortino Ratio Rank: 7979
Sortino Ratio Rank
TPR Omega Ratio Rank: 8484
Omega Ratio Rank
TPR Calmar Ratio Rank: 8888
Calmar Ratio Rank
TPR Martin Ratio Rank: 8888
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ACAD vs. TPR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ACADIA Pharmaceuticals Inc. (ACAD) and Tapestry, Inc. (TPR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ACADTPRDifference

Sharpe ratio

Return per unit of total volatility

-0.07

1.95

-2.02

Sortino ratio

Return per unit of downside risk

0.16

2.30

-2.14

Omega ratio

Gain probability vs. loss probability

1.02

1.35

-0.33

Calmar ratio

Return relative to maximum drawdown

-0.11

4.12

-4.23

Martin ratio

Return relative to average drawdown

-0.22

10.70

-10.91

ACAD vs. TPR - Sharpe Ratio Comparison

The current ACAD Sharpe Ratio is -0.07, which is lower than the TPR Sharpe Ratio of 1.95. The chart below compares the historical Sharpe Ratios of ACAD and TPR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ACADTPRDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.07

1.95

-2.02

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.04

0.75

-0.79

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.09

0.38

-0.46

Sharpe Ratio (All Time)

Calculated using the full available price history

0.06

0.44

-0.38

Drawdowns

ACAD vs. TPR - Drawdown Comparison

The maximum ACAD drawdown since its inception was -96.29%, which is greater than TPR's maximum drawdown of -82.55%. Use the drawdown chart below to compare losses from any high point for ACAD and TPR.


Loading charts...

Drawdown Indicators


ACADTPRDifference

Max Drawdown

Largest peak-to-trough decline

-96.29%

-82.55%

-13.74%

Max Drawdown (1Y)

Largest decline over 1 year

-27.58%

-19.21%

-8.37%

Max Drawdown (3Y)

Largest decline over 3 years

-57.87%

-39.54%

-18.33%

Max Drawdown (5Y)

Largest decline over 5 years

-57.87%

-41.87%

-16.00%

Max Drawdown (10Y)

Largest decline over 10 years

-77.18%

-79.06%

+1.88%

Current Drawdown

Current decline from peak

-63.35%

-13.38%

-49.97%

Average Drawdown

Average peak-to-trough decline

-50.15%

-27.75%

-22.40%

Ulcer Index

Depth and duration of drawdowns from previous peaks

14.63%

7.39%

+7.24%

Volatility

ACAD vs. TPR - Volatility Comparison

The current volatility for ACADIA Pharmaceuticals Inc. (ACAD) is 10.19%, while Tapestry, Inc. (TPR) has a volatility of 17.15%. This indicates that ACAD experiences smaller price fluctuations and is considered to be less risky than TPR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ACADTPRDifference

Volatility (1M)

Calculated over the trailing 1-month period

10.19%

17.15%

-6.96%

Volatility (6M)

Calculated over the trailing 6-month period

26.00%

28.38%

-2.38%

Volatility (1Y)

Calculated over the trailing 1-year period

36.81%

40.80%

-3.99%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

55.52%

40.25%

+15.27%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

62.10%

44.24%

+17.86%

Dividends

ACAD vs. TPR - Dividend Comparison

ACAD has not paid dividends to shareholders, while TPR's dividend yield for the trailing twelve months is around 1.12%.


PositionTTM20252024202320222021202020192018201720162015
ACAD
ACADIA Pharmaceuticals Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
TPR
Tapestry, Inc.
1.12%1.17%2.14%3.53%2.89%1.23%1.09%5.01%3.00%3.06%3.85%4.13%

Financials

ACAD vs. TPR - Financials Comparison

This section allows you to compare key financial metrics between ACADIA Pharmaceuticals Inc. and Tapestry, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00M1.00B1.50B2.00B2.50B20222023202420252026
268.06M
1.92B
(ACAD) Total Revenue
(TPR) Total Revenue
Values in USD except per share items

ACAD vs. TPR - Profitability Comparison

The chart below illustrates the profitability comparison between ACADIA Pharmaceuticals Inc. and Tapestry, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%100.0%202220232024202520260
76.9%
Portfolio components
ACAD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ACADIA Pharmaceuticals Inc. reported a gross profit of 0.00 and revenue of 268.06M. Therefore, the gross margin over that period was 0.0%.

TPR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Tapestry, Inc. reported a gross profit of 1.48B and revenue of 1.92B. Therefore, the gross margin over that period was 76.9%.

ACAD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ACADIA Pharmaceuticals Inc. reported an operating income of -4.62M and revenue of 268.06M, resulting in an operating margin of -1.7%.

TPR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Tapestry, Inc. reported an operating income of 427.50M and revenue of 1.92B, resulting in an operating margin of 22.3%.

ACAD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ACADIA Pharmaceuticals Inc. reported a net income of 3.64M and revenue of 268.06M, resulting in a net margin of 1.4%.

TPR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Tapestry, Inc. reported a net income of 343.80M and revenue of 1.92B, resulting in a net margin of 17.9%.


Frequently Asked Questions


ACAD and TPR have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

TPR has higher volatility (17.15%) compared to ACAD (10.19%). In terms of maximum drawdown, ACAD dropped -96.29% vs TPR's -82.55%.

TPR currently has the higher Sharpe Ratio (1.95 vs -0.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ACAD and TPR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer